Brain Tumors

Department of Neurology, NorthShore University HealthSystem, Glenview, IL.
Disease-a-month: DM (Impact Factor: 0.95). 12/2012; 58(12):678-689. DOI: 10.1016/j.disamonth.2012.08.009
Source: PubMed
5 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Meningiomas are the most common primary brain tumors in adults. Most of them are benign (World Health Organization grade I), slow-growing lesions, but some are classified as atypical (WHO grade II) or malignant (WHO grade III). Surgical resection is curative when complete removal of a benign meningioma is possible. Incompletely resected tumors and high-grade lesions are frequently treated with fractionated radiotherapy or stereotactic radiosurgery. Radiotherapy effectively reduces recurrence rates with limited toxicity. High-grade meningiomas tend to recur following maximal treatment with surgery and radiation. Chemotherapeutic agents, including hydroxyurea, have been used for recurrent disease with marginal efficacy. As the molecular pathogenesis of meningiomas is elucidated, targeted drug therapies may prove useful. Angiogenesis inhibitors, agents that target fundamental cell signaling pathways, somatostatin analogues, and a variety of other molecular treatments appear promising.
    Current Neurology and Neuroscience Reports 06/2009; 9(3):231-40. DOI:10.1007/s11910-009-0034-5 · 3.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, advances in the understanding of low-grade glioma (LGG) biology have driven new paradigms in molecular markers, diagnostic imaging, operative techniques and technologies, and adjuvant therapies. Taken together, these developments are collectively pushing the envelope toward improved quality of life and survival. In this article, the authors evaluate the recent literature to synthesize a comprehensive review of LGGs in the modern neurosurgical era.
    Journal of Neurosurgery 08/2011; 115(5). DOI:10.3171/2011.7.JNS10238 · 3.74 Impact Factor
  • Source
    New England Journal of Medicine 11/2008; 359(17):1850; author reply 1850. DOI:10.1056/NEJMc086380 · 55.87 Impact Factor